To cite this paper use one of the standards below:
Leishmaniasis and trypanosomiasis are parasitic diseases that affect tropical regions and are considered neglected tropical diseases (NTDs).1 These diseases still require the development of more effective and safer therapies.2 Fragment-based drug design (FBDD) emerged as an excellent means to discover promising treatment options. Indazole, the fragment of choice, was subjected to various synthetic transformations and molecular characterization by Nuclear Magnetic Resonance (NMR), Liquid Chromatography-Mass Spectrometry (LC-MS) and High-Resolution Mass Spectrometry (HRMS). Phenotypic biological screening against a panel of parasites (IC₅₀) and test for cytotoxicity (TC50) showed compounds with promising antiparasitic activities. Two libraries of indazoles were afforded from which two hits, compounds 1 (IC50 of 1.62 μΜ against Trypanosoma cruzi) and 2 (IC50 of 12.7 μΜ against Leishmania infantum) were revealed. Their IC50 are comparable to that of benznidazole (1.92 μM) and miltefosine (12.13 μM), which are FDA approved drugs for the treatment of T. cruzi and L. infantum respectively.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper